Status:
COMPLETED
Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborating Sponsors:
Pfizer
Conditions:
Urinary Incontinence
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bo...
Eligibility Criteria
Inclusion
- 18 years or older patients suffering from OAB symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary.
Exclusion
- Other than urge incontinence
- History of prostate/uterine or other female organ cancer
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00143377
Start Date
September 1 2004
End Date
October 1 2005
Last Update
January 27 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.